Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BVI today announced the opening of the BVI Experience Hub, a dedicated facility designed to support ophthalmic training and professional development.
-
KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the...
-
TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...
-
Therini Bio doses first patients in Ph1b trial evaluating novel anti-inflammatory therapy, THN391, in DME, and advances fibrin/VEGF bispecific THN622
-
IQity and Sightpath Medical Partner to Deliver Advanced Ophthalmic Technology to Surgeons Nationwide
IQity partners with Sightpath Medical to bring advanced ophthalmic technology to surgeons throughout the USA
-
Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO’s introduction to the broader ophthalmology community at ASCRS...
-
Eye Summit™ 2026 brings 20+ experts to share how to prevent vision loss, including strategies for macular degeneration, dry eye, glaucoma and brain health
-
Gosselies, Belgium, May 05, 2026 (GLOBE NEWSWIRE) -- Gpr124 represents a promising novel target for improving the integrity and function of the blood-retina barrier (BRB) with the goal of slowing,...
-
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...
-
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...